MA71568A - Forme saline et forme cristalline de dérivé de thiénopyrimidinone - Google Patents

Forme saline et forme cristalline de dérivé de thiénopyrimidinone

Info

Publication number
MA71568A
MA71568A MA71568A MA71568A MA71568A MA 71568 A MA71568 A MA 71568A MA 71568 A MA71568 A MA 71568A MA 71568 A MA71568 A MA 71568A MA 71568 A MA71568 A MA 71568A
Authority
MA
Morocco
Prior art keywords
thienopyrimidinone
derivative
crystalline form
salt
salt form
Prior art date
Application number
MA71568A
Other languages
English (en)
Inventor
Bin Liu
Boyu HU
Kevin X Chen
Original Assignee
Cms Research & Development Pte. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cms Research & Development Pte. Ltd. filed Critical Cms Research & Development Pte. Ltd.
Publication of MA71568A publication Critical patent/MA71568A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/74Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C215/90Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with quaternised amino groups bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MA71568A 2022-08-16 2023-08-15 Forme saline et forme cristalline de dérivé de thiénopyrimidinone MA71568A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210984344 2022-08-16
EP23854433.2A EP4559904A4 (fr) 2022-08-16 2023-08-15 Forme saline et forme cristalline de dérivé de thiénopyrimidinone
PCT/CN2023/113085 WO2024037532A1 (fr) 2022-08-16 2023-08-15 Forme saline et forme cristalline de dérivé de thiénopyrimidinone

Publications (1)

Publication Number Publication Date
MA71568A true MA71568A (fr) 2025-05-30

Family

ID=89940743

Family Applications (1)

Application Number Title Priority Date Filing Date
MA71568A MA71568A (fr) 2022-08-16 2023-08-15 Forme saline et forme cristalline de dérivé de thiénopyrimidinone

Country Status (7)

Country Link
EP (1) EP4559904A4 (fr)
JP (1) JP7801535B2 (fr)
KR (1) KR20250048100A (fr)
CN (1) CN119698409A (fr)
AU (1) AU2023325806A1 (fr)
MA (1) MA71568A (fr)
WO (1) WO2024037532A1 (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2418803C2 (ru) * 2005-10-19 2011-05-20 Киссеи Фармасьютикал Ко., Лтд. Конденсированное гетероциклическое производное, содержащая его лечебная композиция и ее применение в медицине
AP2016009128A0 (en) 2013-10-07 2016-04-30 Bayer Pharma AG Cyclic thienouracil-carboxamides and use thereof
BR112019002513A2 (pt) * 2016-08-08 2019-05-14 Kissei Pharmaceutical Co., Ltd. uso e dosagem de agentes terapêuticos para endometriose
US20230067378A1 (en) * 2018-11-07 2023-03-02 ObsEva S.A. Compositions and methods for the treatment of estrogen-dependent disorders
JP2022543757A (ja) 2019-08-08 2022-10-14 オブセヴァ エス.エー. エストロゲン依存性障害の治療のためのgnrhアンタゴニスト
EP4009977A2 (fr) * 2019-08-08 2022-06-15 ObsEva S.A. Compositions et méthodes de traitement de troubles dépendant des oestrogènes
RS67499B1 (sr) * 2021-02-23 2025-12-31 Cms Res & Development Pte Ltd Fuziono policiklično jedinjenje supstituisane 5-karboksilne kiseline tienopirimidindiona i njegova primena

Also Published As

Publication number Publication date
JP7801535B2 (ja) 2026-01-16
EP4559904A1 (fr) 2025-05-28
AU2023325806A1 (en) 2025-03-06
WO2024037532A1 (fr) 2024-02-22
KR20250048100A (ko) 2025-04-07
CN119698409A (zh) 2025-03-25
EP4559904A4 (fr) 2025-10-15
JP2025526941A (ja) 2025-08-15

Similar Documents

Publication Publication Date Title
EP3947361A4 (fr) Sel et forme cristalline d'un inhibiteur de fak
EP3438099A4 (fr) Sel d'acide pamoïque de vortioxétine et sa forme cristalline
EP4257154A4 (fr) Conjugué à substance bioactive, son procédé de préparation et son utilisation
EP3954693A4 (fr) Forme cristalline d'un inhibiteur d'egfr et procédé de préparation associé
EP3807279A4 (fr) Sels pharmaceutiquement acceptables de sépiaptérine
BRPI1007680A2 (pt) "cristais com baixo e alto ponto de fusão; método de preparo dos mesmos; composição da suspensão e composição da suspensão aquosa"
EP3502103A4 (fr) Forme cristalline, type de sel d'un dérivé de 2-hydro-pyrazole substitué et son procédé de préparation
EA201000104A1 (ru) Производные пиримидина, применимые для лечения воспалительных или аллергических патологических состояний
EP2431355A4 (fr) Nouvelle forme cristalline vi de l'agomélatine son procédé de préparation et son application
LT4313945T (lt) Kristalinė 5-meo-dmt hidrobromido druska
EP4559904A4 (fr) Forme saline et forme cristalline de dérivé de thiénopyrimidinone
IL317275A (en) Collagen compositions and methods of use thereof
MA52792A (fr) Formes cristallines et monohydrate de 6- [(3s,4s)-4-méthyl-1-(pyrimidin-2-ylméthyl) pyrrolidin-3-yl]-3-tétrahydropyran-4-yl-7h-imidazo [1,5-a] pyrazin-8-one
EP3923816A4 (fr) Catégorisation de morphologies de forme d'onde
MA43549A (fr) Alpha-amino esters de dérivé d'hydroxypropylthiazolidine carboxamide, sel et forme cristalline polymorphe correspondants
EP3996707A4 (fr) Formes cristallines d'inhibiteurs de la kallicréine plasmatique
EP4017546A4 (fr) Compositions et méthodes associées pour l'ablation de macrophages m2 et de cellules myéloïdes suppressives
EP3305768A4 (fr) Sel de sodium d'inhibiteur de transporteur d'acide urique et sa forme cristalline
IL284018A (en) Correcting anatomical maps
EP4255431A4 (fr) Formes solide de l'émétine
EP4023620A4 (fr) Composition de marbre artificiel et marbre artificiel l'utilisant
EP4089086A4 (fr) Forme cristalline de dérivé de pyrrolidinyl-urée et son application
EP4108664A4 (fr) Forme cristalline d'inhibiteur de jak et son application
EP4277628C0 (fr) Tasquinomod ou sel pharmaceutiquement acceptable de celui-ci destiné à être utilisé dans le traitement du syndrome myélodysplasique
EP3978486A4 (fr) Forme cristalline d'un inhibiteur de c-met/axl